InvestorsHub Logo
Followers 839
Posts 120436
Boards Moderated 18
Alias Born 09/05/2002

Re: keitern post# 1331

Thursday, 10/12/2006 1:48:04 PM

Thursday, October 12, 2006 1:48:04 PM

Post# of 19309
>What is the "current recombinant factor VIIa product" and who makes it?<

NovoSeven from NVO.

>How do we just step in and "enable the production and pricing of rhFVIIa at appropriate levels for broader utilization"? What does that mean?<

It means that a transgenically-produced FVIIa is likely to have a lower unit cost than NovoSeven, allowing LFB/GTC to capture market share and potentially expand the market for recombinant FVIIa to prophylactic use in addition to at-need use.

>I would appreciate an in depth discussion on rhFVIIa<

We discussed it a bit last week. Here are a few pointers:

#msg-13712057 (NovoSeven)
#msg-13735378 (how coagulation works)
#msg-13763492 (potential competition)
#msg-13784060 (abstract on surgical use)
#msg-13925693 (old NVO PR)

Also, you might want to check LFB’s English-language website:
http://www.lfb.fr/gb/index.asp

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.